ALPRAZOLAM TABLET

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

ALPRAZOLAM

Предлага се от:

SANIS HEALTH INC

АТС код:

N05BA12

INN (Международно Name):

ALPRAZOLAM

дозиране:

0.50MG

Лекарствена форма:

TABLET

Композиция:

ALPRAZOLAM 0.50MG

Начин на приложение:

ORAL

Броя в опаковка:

100

Вид предписание :

Targeted (CDSA IV)

Терапевтична област:

BENZODIAZEPINES

Каталог на резюме:

Active ingredient group (AIG) number: 0115008002; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2021-12-01

Данни за продукта

PRODUCT MONOGRAPH
ALPRAZOLAM
(Alprazolam)
0.25 mg and 0.5 mg Tablets
USP
ANXIOLYTIC - ANTIPANIC
Sanis Health Inc.
Date of Revision:
1 President’s Choice Circle,
June 6, 2019
Brampton, Ontario
L6Y 5S5
www.sanis.com
Control No.: 228154
2
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
5
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
12
DRUG INTERACTIONS
..............................................................................................................
16
DOSAGE AND ADMINISTRATION
..........................................................................................
19
OVERDOSAGE
.............................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
21
STORAGE AND STABILITY
......................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 23
PART II: SCIENTIFIC INFORMATION
...................................................................................
24
PHARMACEUTICAL
INFORMATION......................................................................................
24
CLINICAL TRIALS
...............................................................................